A controversial new cream used to treat vitiligo could soon become available on the NHS. In trials, Ruxolitinib - which carries the brand name Opzelura - was an effective treatment, but also carries potentially serious side-effects.
Vitiligo is a chronic autoimmune disease that causes a loss of pigmentation, leaving smooth, white patches on the skin. Although it does not develop differently in people of different races, it can be more obvious in people with darker skin.
It is not infectious or contagious, but experts say living with vitiligo can be psychologically devastating. Those with vitiligo can often suffer from anxiety, depression and low self-esteem.
